Asia Pacific Genome Editing Market

Market Introduction

Asia Pacific genome editing market is analyzed based on the five major countries such as China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is expected to be the fastest-growing region among all other regions. The growth of the market in Asia Pacific is expected to grow at a faster pace owing to factors such as the increasing need for superior treatment solutions and increasing focus on research and development activities. Additionally, developing healthcare infrastructure and increasing investments in order to boost the research activities are projected to drive the Asia Pacific genome editing market during the forecast period.

In January 2020, after a series of cases of pneumonia in Wuhan, the Chinese health authorities, the capital city of Hubei province (China), announced that a novel coronavirus, officially known as severe acute respiratory syndrome coronavirus (SARS-CoV)-2, was responsible for these cases. COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective therapies for the treatment of COVID 19 have put the healthcare research industry in a critical situation in the Asia Pacific region. However, many of the market players now realized the importance of gene therapy in the treatment of COVID 19 which is expected to raise demand for genome editing during the forecast period.

Asia Pacific Genome Editing Strategic Insights

Strategic insights for the Asia Pacific Genome Editing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Genome Editing Report Scope

Asia Pacific Genome Editing Regional Insights

The geographic scope of the Asia Pacific Genome Editing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The genome editing market in Asia Pacific is expected to grow US$ 1,051.58 million in 2021 to US$ 3,557.63 million by 2028; it is estimated to grow at a CAGR of 19.0% from 2021 to 2028. According to the World Health Organization (WHO), cancer is the biggest cause of death in the region. Overall, the burden of cancer incidence and death is quickly increasing, reflecting both population aging and growth, as well as changes in the prevalence and distribution of the key cancer risk factors, many of which are related to socio-economic development. CANCER TODAY enabled a comprehensive assessment of the cancer burden. In 2020, based on the GLOBOCAN estimates of incidence, mortality, and prevalence for 2020 in 185 countries or territories for 36 cancer types by sex and age group. According to the recent estimates, the incidence of cancer has been increasing at an alarming rate, making hepatocellular carcinoma (HCC the fifth most common cancer in men and the seventh most common cancer in women. HCC is likely to contribute to ~5.6% of all human cancers, thereby increasing the burden in 2020. The HCC is known to be the second leading cause of cancer-related deaths worldwide. Almost 85% of HCCs occur in developing countries. Other types of liver cancers are cholangiocellular carcinoma (CCC), a malignant disease of the liver bile ducts, and hepatoblastoma. Hepatoblastoma is the most common malignant tumor of the liver in children. Thus, a rise in the prevalence of liver diseases, including chronic and acute diseases and microbial infections, increases the demand for liver models. A chromosomal abnormality can be detected in about one out of every 150 live births. Yet even this high incidence represents only a small fraction of chromosome mutations since the vast majority are lethal and result in prenatal death or stillbirth. Indeed, 50% of all first-trimester miscarriages and 20% of all second-trimester miscarriages are estimated to involve a chromosomally abnormal fetus. Although Down syndrome is the most well-known and well-recognized autosomal trisomies, it is only diagnosed in around one out of every 800 live births. Many cancer biology investigations are now using CRISPR as a standard approach. The CRISPR/Cas9 system has been shown to be effective in treating metastatic tumors, which is a big step toward discovering a cancer cure. The CRISPR-LNPs system contains a messenger RNA that encodes for the Cas9 CRISPR enzyme, which operates as molecular scissors to cut the DNA of cells. CRISPR-based studies have opened new doors to treating hereditary or developmental neurological disorders (HNDs) such as fragile X syndrome and Down syndrome. Thus, the increasing factors of genome editing are expected to boost the growth of the genome editing market during the forecast period.

Key Market Segments

In term of technological, CRISPR segment held a larger market share of the genome editing market in 2021. In term of application, genetic engineering segment held a larger market share of the genome editing market in 2021. In term of end user, pharmaceutical and biotechnology companies segment held a larger market share of the genome editing market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the genome editing market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are THERMO FISHER SCIENTIFIC INC.; MERCK KGaA; Lonza; Horizon Discovery Group plc.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; and CRISPR Therapeutics among others.

Reasons to buy report

• To understand the Asia Pacific genome editing market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific genome editing market
• Efficiently plan M&A and partnership deals in Asia Pacific genome editing market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific genome editing market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

Asia Pacific Genome Editing Market Segmentation

Asia Pacific Genome Editing Market – By

Technology

• CRISPR
• TALEN
• Antisense
• Other

Asia Pacific Genome Editing Market – By

Application

• Cell Line Engineering
• Genetic Engineering
• Diagnostic Applications
• Drug Discovery
• Others

Asia Pacific Genome Editing Market – By

End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations (CRO's)

Asia Pacific Genome Editing Market – By

Country

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific

Asia Pacific Genome Editing Market – Companies Mentioned

• THERMO FISHER SCIENTIFIC INC.
• MERCK KGaA
• Lonza
• Horizon Discovery Group plc.            
• Integrated DNA Technologies         
• GenScript
• New England Biolabs
• Eurofins Scientific
• CRISPR Therapeutics